Improvement of Rheumatoid Arthritis and Autoimmune Hepatitis in a Patient Treated with the Tumor Necrosis Factor Inhibitor, Etanercept
|
|
- Andrea Walsh
- 5 years ago
- Views:
Transcription
1 CASE REPORT Improvement of Rheumatoid Arthritis and Autoimmune Hepatitis in a Patient Treated with the Tumor Necrosis Factor Inhibitor, Etanercept Kunihiko Umekita 1, Shunichi Miyauchi 1, Shiro Ueno 1, Ichiro Takajo 1, Kazunori Kusumoto 2, Satoru Hasuike 2, Yoshiko Umekita 3, Hiroyuki Tanaka 3, Kenji Nagata 2, Yasuhiro Nagatomo 1, Hiroaki Kataoka 3, Kazuya Shimoda 2 and Akihiko Okayama 1 Abstract We report a case of rheumatoid arthritis (RA) with autoimmune hepatitis (AIH) and Sjogren syndrome (SjS) that was treated with the tumor necrosis factor (TNF) inhibitor, etanercept (ETN). Both RA activity and transaminase levels improved as a result of treatment. Follow-up liver biopsy showed improvement of hepatitis. Although the efficacy of anti-tnf for RA patients with AIH remains controversial, this case suggests that treatment with ETN may result in a favorable clinical course in a certain subset of patients with RA and AIH. Key words: autoimmune hepatitis, rheumatoid arthritis, anti-tnf therapy () () Introduction Tumor necrosis factor (TNF) is thought to play a critical role in the pathogenesis of chronic inflammatory diseases, such as rheumatoid arthritis (RA) (1). Several biologic agents such as etanercept (ETN), a soluble TNF receptor, and infliximab, an anti-tnf-α antibody, inhibit the function of TNF and improve the quality of life of patients with RA (2). Anti-TNF therapies are now used not only for RA, but also for chronic inflammatory diseases like Crohn s disease and ankylosing spondylitis (3). Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease. AIH results from a complex interaction involving a triggering factor, autoantigens, genetic predisposition, and immunoregulatory networks (4, 5). Corticosteroid and immunosuppressants are generally effective in AIH (4, 6, 7). When inflammation can not be controlled, however, progression from chronic hepatitis to cirrhosis is frequently seen and hepatocellular carcinoma may appear at the end stage (4). The imbalance of Th1/Th2 cytokines has been associated with the pathogenesis of AIH, with researchers reporting that Th1 cytokines such as TNF-α are more predominant than Th2 cytokines in the liver of patients with active AIH (8-10). Therefore, anti-tnf agents can be one of the options for AIH treatment theoretically; however, a case of AIH suspected of resulting from anti-tnf agents has also been reported (11). The contribution of cytokines such as TNF to the pathogenesis of AIH may be complex and the efficacy of anti-tnf agents for AIH remains controversial. Here, we report that administration of ETN to a patient with RA and AIH resulted in improvement of both RA and AIH, which suggests that ETN can result in a favorable clinical course in a certain subset of patients with RA and AIH. Division of Rheumatology, Infectious Diseases, and Laboratory Medicine, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan, Division of Gastroenterology and Hematology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan and Section of Oncopathology and Regenerative Biology, Faculty of Medicine, University of Miyazaki, Japan Received for publication November 22, 2010; Accepted for publication February 17, 2011 Correspondence to Dr. Akihiko Okayama, okayama@med.miyazaki-u.ac.jp 1245
2 Figure 1. Clinical course. AST: aspartate aminotransferase, ALT: alanine aminotransferase, DAS28: disease activity score in 28 joints, CRP: C-reactive protein Case Report A 52-year-old woman presented to our hospital in 1987 complaining of morning stiffness, multiple joint and bilateral parotid gland swelling. She was diagnosed as having RA and Sjogren syndrome (SjS). Because her transaminase levels were moderately elevated (AST 95 IU/mL, normal range 9-32; ALT 84 IU/mL, normal range 5-46), liver biopsy was performed. Results showed a mild inflammation, prompting a pathological diagnosis of non-specific reactive hepatitis due to RA and/or SjS. She was treated with lobenzarit disodium. In 1992, tests revealed the elevated levels of AST (319 IU/mL) and ALT (312 IU/mL). The patient tested positive for anti-nuclear antibody (1 : 160, homogenous type) and anti-smooth muscle antibody. Her serum IgG was elevated (3,540 mg/dl). Anti-mitochondrial antibody (AMA) was negative. Serological markers of viral hepatitis (hepatitis C virus antibody, hepatitis B surface antigen and hepatitis B surface antibody) were negative. Laparoscopy revealed multiple nodular change on the liver surface. Liver biopsy showed piecemeal necrosis with the infiltration of plasma cells in portal areas. Based on these data and reference to the criteria established by the Japanese Ministry of Health, Labour and Welfare Research Committee on AIH in1992, a diagnosis of AIH was made (12). The AIH was treated with oral prednisolone (PSL) (30 mg/day) and serum transaminase levels decreased to normal limits (AST 12 IU/mL and ALT 9 IU/mL). Low-dose PSL (6-10 mg/day) was continued from 1993 to Lobenzarit disodium proved ineffective in controlling RA activity, and the patient was administered several different anti-rheumatic drugs, such as auranofin, bucillamine, salazosulfapyridine, and mizoribine. However, administration was discontinued due to liver and renal dysfunction. Methotrexate was rejected in consideration of the underlying AIH, and the patient was placed on a low-dose PSL. A minimum of 6 mg/day was required to prevent the increase of AST and ALT. In 2006, RA activity increased gradually. The patient was admitted to our hospital for treatment with anti-tnf agents in June, 2007 (Fig. 1). Disease Activity Score in 28 joints (DAS28) was high at 6.4 (Table 1). SjS symptoms such as dry eyes and mouth were minimal. Serum transaminase levels were slightly increased (AST 59 IU/mL and ALT 58 IU/mL). Liver biopsy performed to assess the status of liver damage before starting anti-tnf agent treatment. Pathological examination of liver showed inflammation of periportal areas with infiltration of plasma cells and piecemeal necrosis suggesting active AIH (Fig. 2-a, b). The patient was exhibiting high RA activity and severe symptoms; however, due to concern about administering anti-tnf treatment to a patient with active AIH, ETN (25 mg, twice a week) was started after obtaining informed consent. PSL dosage was the same before and after ETN treatment. The signs and symptoms of RA quickly improved. DAS28 and C-reactive protein (CRP) values decreased, as did transaminase and serum IgG levels, though more gradually (Fig. 1, Table 1). In May 2008, forty-four weeks after the start of ETN, DAS28 became 2.3. Most of the symptoms of RA had disappeared. This patient com- 1246
3 Table 1. plained only morning stiffness after ETN treatment. The dosage of PSL was decreased to 5 mg/day and serum transaminases values remained low. Follow-up liver biopsy was performed and marked improvement of inflammation to periportal areas was noted (Fig. 2-c, d). In July 2010, 126 weeks after the start of ETN, RA and AIH were in remission even though the dosage of PSL had been decreased to 3 mg/day. The minimal symptoms of dry eyes and mouth, noted prior to the start of ETN treatment in 2007, remained unchanged. Discussion A case of active RA with AIH and SjS was treated with ETN. RA activity in the patient decreased quickly and clinical remission (DAS28<2.6) has continued for 3 years without other anti-rheumatic drugs. SjS symptoms were unaffected by ETN treatment. In addition to AIH, several possible causes exist for the liver dysfunction seen in the present case, including liver manifestations of RA or SjS and drug-induced liver dysfunction. In this case, it was difficult to differentiate AIH and reactive or non-specified hepatitis associated with RA or SjS initially, because patients with RA or SjS frequently show positive ANA and an increased level of IgG, which are important in the diagnosis of AIH. Therefore, histology obtained from liver biopsy was important in the present case (13-15). The histology of hepatic lesions due to SjS or RA has been reported as non-specific inflammation with infiltration of mononuclear cells and with fatty change (13, 16, 17). SjS is also known to be associated with primary billiary cirrhosis (16, 18). However, the present case tested positive for anti-smooth muscle antibody, but negative for AMA. Moreover, liver biopsy of this case revealed the interface hepatitis with infiltration of plasma cells and piecemeal necrosis in the periportal area. These results supported the diagnosis of AIH in this case. Drug-induced liver dysfunction was also considered unlikely in light of the clinical course and histology of the liver. The liver biopsy in 2008 revealed the mild infiltration of mononuclear cells, however, the degree of inflammation was much less than that in In addition, the levels of transaminases decreased even after the dosage of PSL had been decreased to 3 mg/day. Therefore, improvement of AIH after ETN treatment was suggested. The role of TNF in the pathogenesis of AIH remains unclear. Th1 cytokines, such as TNF-α were reported to be predominant in the liver of patients with AIH (6). TNF-α has been reported to activate cytotoxic T lymphocytes and/ or macrophages, and their cellular autoimmunity results in hepatocellular injury (6, 7, 9, 10). These activated cells were also reported to produce B-cell activating factor belonging to the tumor necrosis factor family (BAFF), which stimulates B-cell inducing humoral autoimmunity (19). In theory, therefore, TNF inhibitor may be effective in the treatment of AIH; however, no reports have been published to date showing TNF inhibitor to be clinically useful as a treatment for AIH. On the contrary, development of AIH in a patient with ankylosing spondylitis treated with infliximab, an agent of anti-tnf-α antibody, has been reported (20). Another report showed that a patient with active RA and SjS, treated with ETN developed liver dysfunction and was diagnosed as AIH (11). These reports suggest that caution is necessary in the treatment of autoimmune diseases with AIH using anti- TNF agents. In conclusion, the anti-tnf agent, ETN was effective in 1247
4 Figure 2. Histopathological findings in liver biopsy (Hematoxylin and Eosin staining). a-b) Expanded portal tracts associated with chronic inflammatory infiltrate, including a significant number of plasma cells, and fibrosis were found. Fibrosis extended into lobules, partly forming bridging fibrosis, suggestive of commencing cirrhosis. Piecemeal necrosis and lymphoplasmacytic infiltration into the periportal area and lobules was revealed before etanercept (ETN) treatment in c-d) Moderate infiltration of plasmacytes and lymphocytes was seen in the periportal area. A small number of multinucleated hepatocytes were intermingled. Several thin fibrous septa were also noted, showing portal-center bridging. Neither collapse nor rosette formation was identified in this specimen. Improvement of hepatitis with localized infiltration of inflammatory cells in the periportal area was observed at 44 weeks after ETN treatment. the treatment of active RA in a patient with SjS and AIH. ETN treatment did not exacerbate AIH and it was possible to decrease the dosage of PSL. Further study is required on a large number of subjects to confirm the efficacy of ETN in patients with active RA and AIH. The authors state that they have no Conflict of Interest (COI). References 1. Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-tnf therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol 18: 59-80, Feldmann M. Development of anti-tnf therapy for rheumatoid arthritis. Nat Rev immunol 2: , Stokes DG, Kremer JM. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin Arthritis Rheum 33: 1-18, Krawitt EL. Autoimmune hepatitis. N Engl J Med 354: 54-66, Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 41: 31-37, Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 35: 7-13, Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 43: S132-S144, Maggiore G, De Benedetti F, Massa M, Pignatti P, Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. J Pediatr Gastroenterol Nutr 20: 23-27, Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 96: , Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol 14: , Harada K, Akai Y, Koyama S, Ikenaka Y, Saito Y. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Clin Rheumatol 27: , Ohta Y. Report of the research subgroup of autoimmune hepatitis/ primary biliary cirrhosis. Gastroenterol Jpn 28 Suppl 4: , Kojima H, Uemura M, Sakurai S, et al. Clinical features of liver disturbance in rheumatoid diseases: clinicopathological study with special reference to the cause of liver disturbance. J Gastroenterol 1248
5 37: , Kooy A, de Heide LJ, Engelkens HJ, et al. How to diagnose autoimmune hepatitis in systemic lupus erythematosus? Hepatology 23: , Matsumoto T, Morizane T, Aoki Y, et al. Autoimmune hepatitis in primary Sjogren s syndrome: Pathological study of the livers and labial salivary glands in 17 patients with primary Sjogren s syndrome. Pathol Int 55: 70-76, Matsumoto T, Kobayashi S, Shimizu H, et al. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver 20: , Abraham S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis 63: , Aoki A, Kirino Y, Ishigatsubo Y, Senuma A, Nagaoka S. Liver involvement in primary Sjogren s syndrome. Jpn J Clin Immunol 27: , 2004 (in Japanese, Abstract in English). 19. Migita K, Abiru S, Maeda Y, et al. Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol 68: , Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 187: , The Japanese Society of Internal Medicine
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationA Case of Autoimmune Hepatitis with Antimitochondrial Antibody and No Detectable Antinuclear Antibody
FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF St. Marianna Med. J. Case Report Vol. 32, pp. 33 38, 2004 FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF A Case
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationAutoimmune Hepatitis in Clinical Practice
1 Autoimmune Hepatitis in Clinical Practice Atif Zaman, MD MPH Professor of Medicine Senior Associate Dean for Clinical and Faculty Affairs School of Medicine Oregon Health & Science University Disclosure
More informationBasic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk Fatty liver disease Is there fatty
More informationImmunopathogenesis: Insights for Current and Future Therapies
REVIEW Immunopathogenesis: Insights for Current and Future Therapies John M. Vierling, M.D., F.A.C.P. Autoimmune hepatitis (AIH) is a chronic, progressive, necroinflammatory disease caused by loss of tolerance
More informationOriginal Article Autoimmune hepatitis in patients with primary Sjögren s syndrome: a series of two-hundred and two patients
Int J Clin Exp Pathol 2010;3(6):582-586 www.ijcep.com /IJCEP1004002 Original Article Autoimmune hepatitis in patients with primary Sjögren s syndrome: a series of two-hundred and two patients Julie K.
More informationCase #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis
45 year old woman presented with abnormal liver function tests Liver Biopsy to r/o autoimmune hepatitis Further down. ANA 1: 160; ASMA 1:80 ANA 1: 160; ASMA 1:80 IgG = 14.5 g/l (upper normal range: 16)
More informationORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:98 103 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Serologic Markers Do Not Predict Histologic Severity or Response to Treatment in Patients With
More informationAutoimmune Hepatitis: Histopathology
REVIEW Autoimmune Hepatitis: Histopathology Stephen A. Geller M.D.*, Autoimmune hepatitis (AIH), a chronic hepatic necroinflammatory disorder, occurs mostly in women. AIH is characterized by prominent
More informationComparing Efficacy Between Regimens in the Initial Treatment of Autoimmune Hepatitis
Elmer Original Article ress Comparing Efficacy Between Regimens in the Initial Treatment of Autoimmune Hepatitis Chijioke Enweluzo a, b, Fahad Aziz a, Amit Mori a Abstract Background: Autoimmune hepatitis
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationAutoimmune Hepatitis. Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern. November 14th, 2018
Autoimmune Hepatitis Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern November 14th, 2018 AIH - Definition Manns MP J Hepatol 2015, vol 62, P 100-111 AIH - Definition Autoimmune hepatitis (AIH) is
More informationAutoimmune Hepatitis. What Drug and for How Long? Hepatology Day May 30 th, 2015
Autoimmune Hepatitis What Drug and for How Long? Rajaa Chatila, MD Associate Professor of Medicine Director, Internal Medicine Residency Program Lebanese American University Hepatology Day May 30 th, 2015
More informationClinical Study Evaluation and Clinical Validity of a New Questionnaire for Mikulicz s Disease
International Rheumatology Volume 2, Article ID 283459, pages doi:1.1155/2/283459 Clinical Study Evaluation and Clinical Validity of a New Questionnaire for Mikulicz s Disease Motohisa Yamamoto, 1 Hiroki
More informationACP-BSG meeting The liver in systemic inflammatory disorders. Dr Adrian C Bateman Southampton University Hospitals NHS Trust
ACP-BSG meeting 10.12.09 The liver in systemic inflammatory disorders Dr Adrian C Bateman Southampton University Hospitals NHS Trust Wide range of diseases General inflammatory disorders Connective tissue
More informationAutoimmune Liver Diseases
2nd Pannonia Congress of pathology Hepato-biliary pathology Autoimmune Liver Diseases Vera Ferlan Marolt Institute of pathology, Medical faculty, University of Ljubljana Slovenia Siofok, Hungary, May 2012
More informationHangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam
Clinical Aspects of Primary Biliary Cirrhosis Hangzhou, 15 March 2008 Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Epidemiology of Primary
More informationLIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA
LIVER SPECIALTY CONFERENCE USCAP 2016 Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA Nothing to disclose Case History 47-year-old male, long standing ileal
More informationPBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
More informationEvaluation of the revised versus the simplified scoring system in patients with autoimmune hepatitis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 131-136, 2014 Evaluation of the revised versus the simplified scoring system in patients with autoimmune hepatitis YI LI, MILIN PENG and GUOZHONG GONG Institute
More informationDomenico ALVARO, MD Sapienza, University of Rome, Italy. Congresso Nazionale della Società Italiana di GastroReumatologia, Roma, 25 Giugno 2015.
Epatite autoimmune e sindrome da "overlap Domenico ALVARO, MD Sapienza, University of Rome, Italy Congresso Nazionale della Società Italiana di GastroReumatologia, Roma, 25 Giugno 2015. AUTOIMMUNE HEPATITIS
More informationIntroduction. Kaoru Omori 1 Masahiro Kan 1. Kanako Yoshida
Clin J Gastroenterol (2016) 9:312 318 DOI 10.1007/s28-016-0676-1 CASE REPORT Familial occurrence of autoimmune liver disease with overlapping features of primary biliary cholangitis and autoimmune hepatitis
More informationPatient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationSerologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I
Autoimmune Hepatitis By Thomas Frazier Objective What we need to know about AIH Diagnosis Treatment Difficulties in both Liver transplantation concerns AASLD Guidelines: Hepatology. 2010 Jun;51(6):2193-213.
More informationdoi: /s
doi: 10.1007/s10620-013-2734-6 Harada - 1 - Clinicopathological significance of serum fractalkine in primary biliary cirrhosis Kenichi Harada 1), Yuko Kakuda 1), Minoru Nakamura 2), Shinji Shimoda 3),
More informationAutoimmune Hepatitis: Clinical Overview and Pathological Findings
6 Jan 2018 Vol 11 No.1 North American Journal of Medicine and Science Review Autoimmune Hepatitis: Clinical Overview and Pathological Findings Simpal Gill, MD* Pathology Laboratory services, Houston Medical
More informationActemra (tocilizumab) CG-DRUG-81
Market DC Actemra (tocilizumab) CG-DRUG-81 Override(s) Prior Authorization Approval Duration 1 year Medications Line of Business Quantity Limit Actemra (tocilizumab) vials VA MCD and All L-AGP May be subject
More informationTwo Cases of Primary Sclerosing Cholangitis Overlapping with Autoimmune Hepatitis in Adults
CASE REPORT Two Cases of Primary Sclerosing Cholangitis Overlapping with Autoimmune Hepatitis in Adults Go Igarashi 1, Tetsu Endo 1, Kenichiro Mikami 1, Naoya Sawada 1,RyuSatake 1, Rie Ohta 1, Juichi Sakamoto
More informationSlide 7 demonstrates acute pericholangitisis with neutrophils around proliferating bile ducts.
Many of the histologic images and the tables are from MacSween s Pathology of the Liver (5 th Edition). Other images were used from an online source called PathPedia.com. A few images from other sources
More informationDiagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful?
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:935 940 Diagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful? REGAN L. EBBESON* and RICHARD
More informationBasic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk @robdgol FATTY LIVER DISEASE Brunt
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France 41 year-old woman, coming to emergency department for fatigue
More informationAutoimmune hepatitis
Autoimmune hepatitis: Autoimmune hepatitis a spectrum within a spectrum Alastair Burt Professor of Pathology and Dean of Clinical Medicine Newcastle University Spectrum of autoimmune liver disease Autoimmune
More informationbudesonide, 3mg, gastro-resistant capsules (Budenofalk ) SMC No. (1043/15) Dr Falk Pharma UK Ltd
budesonide, 3mg, gastro-resistant capsules (Budenofalk ) SMC No. (1043/15) Dr Falk Pharma UK Ltd 10 April 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationDiagnostic Criteria for Autoimmune Hepatitis : Historical Review and Present Problems
Jikeikai Med J 2011 ; 58 : 89-93 Review Diagnostic Criteria for Autoimmune Hepatitis : Historical Review and Present Problems Mikio Zeniya and Hiroki Takahashi Department of Gastroenterology and Hepatology,
More informationCitation The Journal of dermatology, 37(1), available at
NAOSITE: Nagasaki University's Ac Title Author(s) Case of localized scleroderma assoc Muroi, Eiji; Ogawa, Fumihide; Yamao Sato, Shinichi Citation The Journal of dermatology, 37(1), Issue Date 2010-01 URL
More informationMinocycline as a Cause of Drug-Induced Autoimmune Hepatitis Report of Four Cases and Comparison With Autoimmune Hepatitis
Anatomic Pathology / MINOCYCLINE-INDUCED AUTOIMMUNE HEPATITIS Minocycline as a Cause of Drug-Induced Autoimmune Hepatitis Report of Four Cases and Comparison With Autoimmune Hepatitis Neal S. Goldstein,
More informationLinda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology
Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology Nonalcoholic steatohepatitis and Fatty Liver Disease Liver manifestations of the obesity epidemic Changes
More informationClinical characteristics and response to therapy of autoimmune hepatitis in an urban Latino population
Gastroenterology and Hepatology From Bed to Bench. 2016 RIGLD, Research Institute for Gastroenterology and Liver Diseases BRIEF REPORT Clinical characteristics and response to therapy of autoimmune hepatitis
More informationACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationBiliary tract diseases of the liver
Biliary tract diseases of the liver Digestive Diseases Course Bucharest 2016 Rob Goldin r.goldin@imperial.ac.uk How important are biliary tract diseases? Hepatology 2011 53(5):1608-17 Approximately 16%
More informationAuthor(s) Nakao, Kazuhiko; Kanematsu, Takashi. Citation Transplantation proceedings, 42(7),
NAOSITE: Nagasaki University's Ac Title Author(s) Macrophage-dominant sialadenitis in associated myelopathy after living- Nakamura, Hideki; Ichikawa, Tatsuki Atsushi; Iwamoto, Naoki; Matsuzaki, Yamasaki,
More informationTest Name Results Units Bio. Ref. Interval
135091662 Age 45 Years Gender Male 29/8/2017 120000AM 29/8/2017 100215AM 29/8/2017 110825AM Ref By Final RHEUMATOID AUTOIMMUNE COMREHENSIVE ANEL ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF), SERUM ----- 20-60
More informationEfficacy of pegylated interferon plus ribavirin in combination with corticosteroid for two cases of combined hepatitis C and autoimmune hepatitis
Clin J Gastroenterol (2012) 5:141 145 DOI 10.1007/s28-012-0295-4 CASE REPORT Efficacy of pegylated interferon plus ribavirin in combination with corticosteroid for two cases of combined hepatitis C and
More informationNovel Therapies in Autoimmune Hepatitis
Novel Therapies in Autoimmune Hepatitis Paul W. Rassam,MD Ass. Clinical Professor of Medicine Div. of Gastroenterology and Hepatology St George Hospital University Medical Center University of Balamand
More informationPITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017
CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017 I HAVE NOTHING TO DISCLOSE Linda Ferrell PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES Linda Ferrell, MD, UCSF THE PROBLEM
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More informationHwajeong Lee, MD, Robert T. Stapp, DO, Adrian H. Ormsby, MD, and Veena V. Shah, MD
Anatomic Pathology / Overlap Syndrome The Usefulness of IgG and IgM Immunostaining of Periportal Inflammatory Cells (Plasma Cells and Lymphocytes) for the Distinction of Autoimmune Hepatitis and Primary
More informationWhy to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?
Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently
More informationThe Efficacy of Corticosteroid Therapy in a Patient with Nonalcoholic Steatohepatitis Overlapping Autoimmune Hepatitis: A Case Report
doi: 10.2169/internalmedicine.8887-17 Intern Med Advance Publication http://internmed.jp CASE REPORT The Efficacy of Corticosteroid Therapy in a Patient with Nonalcoholic Steatohepatitis Overlapping Autoimmune
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091593 Age 25 Years Gender Male 30/8/2017 91600AM 30/8/2017 93946AM 31/8/2017 84826AM Ref By Final COLLAGEN DISEASES ANTIBODY ANEL ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF),
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationScottish Medicines Consortium
Scottish Medicines Consortium etanercept 25mg vial of powder for subcutaneous injection (Enbrel ) (No. 212/05) Wyeth New indication: severe active ankylosing spondylitis inadequately controlled by conventional
More informationRheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon
Rheumatology 2005; 1 of 5 Rheumatology Advance Access published April 26, 2005 Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of
More informationRheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904)
Rheumatoid Arthritis Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904) 503-6999. 1 Disclosures Speaker Bureau: Abbvie 2 Objectives Better understand the pathophysiology
More informationWhat will we discuss today?
Autoimmune diseases What will we discuss today? Introduction to autoimmune diseases Some examples Introduction to autoimmune diseases Chronic Sometimes relapsing Progressive damage Epitope spreading more
More informationA Single Center Review of the Use of Mycophenolate Mofetil in the Treatment of Autoimmune Hepatitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1036 1040 A Single Center Review of the Use of Mycophenolate Mofetil in the Treatment of Autoimmune Hepatitis JONATHAN T. HLIVKO, MITCHELL L. SHIFFMAN, R.
More informationKey Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto
Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis
More informationHow to Approach a Medical Liver Biopsy. 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology. Sarajevo, 6 th -7 th November 2015
1 A Brief Introduction to the Liver Sessions 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology Sarajevo, 6 th -7 th November 2015 Stefan Hübscher, Institute of Immunology & Immunotherapy,
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationMechanisms of Autontibodies
Mechanisms of Autontibodies Production in Rheumatic Diseases Eisa Salehi PhD Tehran University of Medical Sciences Immunology Department Introduction Rheumatic diseases: Cause inflammation, swelling, and
More informationNew Therapeutic Perspectives in Sjögren's Syndrome
New Therapeutic Perspectives in Sjögren's Syndrome Claudio Vitali Chairman of the EULAR Task Force for Disease Activity Criteria in Sjögren s Syndrome. Member of the Steering Committee for the ACR- EULAR
More informationHepatotoxicity from Biologics? Ross Pierce, M.D. Division of Hematology, OBRR/CBER/FDA
Hepatotoxicity from Biologics? Ross Pierce, M.D. Division of Hematology, OBRR/CBER/FDA Disclaimer The findings and conclusions in this presentation have not been formally disseminated by the Food and Drug
More informationIn 1993, the International Autoimmune Hepatitis Group
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:417 421 Validation and Modification of Simplified Diagnostic Criteria for Autoimmune Hepatitis in Children ELIZABETH MILETI,* PHILIP ROSENTHAL,*, and MARION
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic
More informationLiver Biopsy in Chronic Viral Hepatitis (B And C) and Autoimmune Hepatitis Referred to Shahid Sadoughi Hospital Yazd, Iran
Original Article Liver Biopsy in Chronic Viral Hepatitis (B And C) and Autoimmune Hepatitis Referred to Shahid Sadoughi Hospital Yazd, Iran * Shokouh Taghipour Zahir,** Jamshid Ayatollahi From Department
More informationViral Hepatitis (I) Luigi Terracciano Department of Pathology University Hospital Basel. Basel,
Viral Hepatitis (I) Luigi Terracciano Department of Pathology University Hospital Basel Basel, 19. 04. 2016 Definition Hepatitis means inflammation of the liver characterized by a variable combination
More informationNews. Laboratory. CHANGES IN CARDIAC TROPONIN I REPORTING Gene Shaw, MD, Annu Khajuria, PhD. Inside This Issue
Laboratory News Inside This Issue CHANGES IN CARDIAC TROPONIN I REPORTING...1 FOUR NEW SEROLOGY TESTS FOR AUTOIMMUNE LIVER DISEASES...3 INSULIN LIKE GROWTH FACTOR-1 (IGF-1) METHOD CHANGES...6 CHANGES IN
More informationPancreatic exocrine insufficiency: a rare cause of nonalcoholic steatohepatitis
Pancreatic exocrine insufficiency: a rare cause of nonalcoholic steatohepatitis Naoki Tanaka 1, Akira Horiuchi 2, Takahide Yokoyama 3, Shigeyuki Kawa 1, and Kendo Kiyosawa 1 1 Department of Gastroenterology,
More informationTitle: Anti-programmed cell death-1 antibody as a new serological marker for type
1 Title: Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis. Short running title: Anti-PD-1 antibody and type 1 AIH. Authors: Kazuyuki Matsumoto, Yasuhiro
More informationImmunoglobulin G4-Related Disease with Several Inflammatory Foci
CASE REPORT Immunoglobulin G4-Related Disease with Several Inflammatory Foci Akira Sakamaki 1, Kenya Kamimura 1, Kazuhiko Shioji 1, Junko Sakurada 2, Takeshi Nakatsue 3, Yoko Wada 3, Michitaka Imai 1,
More informationHOW TO DEAL WITH THOSE ABNORMAL LIVER ENZYMES David C. Twedt DVM, DACVIM Colorado State University Fort Collins, CO
HOW TO DEAL WITH THOSE ABNORMAL LIVER ENZYMES David C. Twedt DVM, DACVIM Colorado State University Fort Collins, CO The identification of abnormal liver enzymes usually indicates liver damage but rarely
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationAutoimmune hepatitis (AIH) is a rare disease, yet it. Fulminant Hepatic Failure as the Initial Presentation of Acute Autoimmune Hepatitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:625 631 Fulminant Hepatic Failure as the Initial Presentation of Acute Autoimmune Hepatitis WILLIAM R. KESSLER,* OSCAR W. CUMMINGS, GEORGE ECKERT, NAGA CHALASANI,*
More informationHistopathology of De Novo Autoimmune Hepatitis
LIVER TRANSPLANTATION 18:811-818, 2012 ORIGINAL ARTICLE Histopathology of De Novo Autoimmune Hepatitis Ananya Pongpaibul, 1 Robert S. Venick, 2 Sue V. McDiarmid, 3 and Charles R. Lassman 4 1 Department
More informationImmunological Aspect of Ozone in Rheumatic Diseases
Immunological Aspect of Ozone in Rheumatic Diseases Prof. Dr. med. Z. Fahmy Chief Consulting Rheumatologist Augusta Clinic for Rheumatic Diseases And Rehabilitation Bad Kreuznach Germany Rheumatoid arthritis
More informationRheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011
Rheumatoid Arthritis Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011 The security of experience. The power of innovation. www.rgare.com Case Study
More informationReactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs
International Journal of Rheumatic Diseases 2016; 19: 470 475 ORIGINAL ARTICLE Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic
More information2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.
Making Room for Rheumatology James J. Nocton, MD Disclosures I have nothing to disclose Rheumatic Diseases of Childhood Juvenile Idiopathic Arthritis (JIA) Systemic Lupus Erythematosus (SLE) Juvenile Dermatomyositis
More informationCase Report Pulmonary Sarcoidosis following Etanercept Treatment
Case Reports in Rheumatology Volume 2012, Article ID 724013, 4 pages doi:10.1155/2012/724013 Case Report Pulmonary Sarcoidosis following Etanercept Treatment Kuljeet Bhamra and Richard Stevens Department
More informationLong-term Outcome of Autoimmune Pancreatitis after Oral Prednisolone Therapy
ORIGINAL ARTICLE Long-term Outcome of Autoimmune Pancreatitis after Oral Prednisolone Therapy Takayoshi Nishino 1, Fumitake Toki 2,HiroyasuOyama 3, Kyoko Shimizu 1 and Keiko Shiratori 1 Abstract Objective
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. Today s Date: Date of HSCT for which this form is being completed:
Juvenile Idiopathic Arthritis Pre-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic, allogeneic,
More informationSuspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane.
ISPUB.COM The Internet Journal of Anesthesiology Volume 25 Number 1 Suspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane. V Sampathi,
More informationERROR CORRECTION FORM
Juvenile Idiopathic Arthritis Pre-HSCT Data Sequence Number: Registry Use Only Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic, allogeneic, syngeneic unrelated related
More informationTaio Naniwa, 1 Shinya Tamechika, 1 Shiho Iwagaitsu, 1 Shinji Maeda, 1 and Hiroyuki Togawa Introduction. 2. Case Presentation
Case Reports in Rheumatology Volume 213, Article ID 923497, 4 pages http://dx.doi.org/1.1155/213/923497 Case Report Successful Use of Higher-Dose Etanercept for Multirefractory Systemic Flare of Adult-Onset
More informationBSG/ACP annual course Royal College of Pathologists Infections and Inflammations of the Hepato-Biliary System Hepatitis B and D
BSG/ACP annual course Royal College of Pathologists Infections and Inflammations of the Hepato-Biliary System Hepatitis B and D Amar Paul Dhillon Royal Free & University College Medical School Thurs 10
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationJournal of Asian Scientific Research
Journal of Asian Scientific Research journal homepage: http://aessweb.com/journal-detail.php?id=5003 COULD SERUM LAMININ REPLACE LIVER BIOPSY AS GOLD STANDARD FOR PREDICTING SIGNIFICANT FIBROSIS IN PATIENTS
More informationLIVER DISEASES. Pathology Department, Zhejiang University School of Medicine,
LIVER DISEASES Pathology Department, Zhejiang University School of Medicine, 马丽琴,maliqin198@zju.edu.cn Viral Hepatitis Cirrhosis of liver Liver cancer Viral Hepatitis DEFINITION Primary hepatic infections
More informationACTEMRA (tocilizumab)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Actemra is an agent in the class of drugs known as biologic disease modifiers. It is used to treat adult onset rheumatoid (RA) arthritis, polyarticular
More informationA Case of Adult Autoimmune Hepatitis with Histological Features of Giant Cell Hepatitis
CASE REPORT A Case of Adult Autoimmune Hepatitis with Histological Features of Giant Cell Hepatitis Hiroki Hayashi 1, Ryoichi Narita 1, Masaaki Hiura 1, Shintaro Abe 1, Akinari Tabaru 1, Akihide Tanimoto
More informationChronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths
Chronic Biliary Disease Dr Susan Davies & Dr Bill Griffiths Chronic Biliary Disease Terminology is confusing with pathologists and hepatologists using the same language BUT with different meanings. Chronic
More informationAutoimmune Hepatitis: Recent Advances in the Pathogenesis and New Diagnostic Guidelines in Japan
REVIEW ARTICLE Autoimmune Hepatitis: Recent Advances in the Pathogenesis and New Diagnostic Guidelines in Japan Hiromasa Ohira, Kazumichi Abe, Atsushi Takahashi and Hiroshi Watanabe Abstract Autoimmune
More informationBachelor of Chinese Medicine ( ) AUTOIMMUNE DISEASES
Bachelor of Chinese Medicine (2002 2003) BCM II Dr. EYT Chan February 6, 2003 9:30 am 1:00 pm Rm 134 UPB AUTOIMMUNE DISEASES 1. Introduction Diseases may be the consequence of an aberrant immune response,
More informationWarm Autoantibodies in a Patient with Hemophagocytic Lymphohistiocytosis: A Case Report
Warm Autoantibodies in a Patient with Hemophagocytic Lymphohistiocytosis: A Case Report Emily Coberly, MD Department of Pathology and Anatomical Sciences University of Missouri Columbia April 30, 2013
More informationPrototypes of autoimmune hepatitis and sclerosing cholangitis in childhood
RIUNIONE MONOTEMATICA AISF 2013 Personalizzazione della Cura in Epatologia 17-19 ottobre 2013, PISA Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood La sottoscritta dichiara di
More informationTumor Necrosis Factor-alpha Antagonists in the Treatment of Secondary Amyloidosis. Gulen Hatemi Istanbul University
Tumor Necrosis Factor-alpha Antagonists in the Treatment of Secondary Amyloidosis Gulen Hatemi Istanbul University TNF-alpha blockage in AA amyloidosis TNF induces SAA production in hepatocytes during
More information